United States - English - NLM (National Library of Medicine)

teva pharmaceuticals, inc. - lubiprostone (unii: 7662kg2r6k) (lubiprostone - unii:7662kg2r6k) - lubiprostone capsules are indicated for the treatment of chronic idiopathic constipation (cic) in adults. lubiprostone capsules are indicated for the treatment of opioid-induced constipation (oic) in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation. limitations of use: effectiveness of lubiprostone capsules in the treatment of opioid-induced constipation in patients taking diphenylheptane opioids (e.g., methadone) has not been established [see clinical studies (14.2)]. lubiprostone capsules are indicated for the treatment of irritable bowel syndrome with constipation (ibs-c) in women at least 18 years old. lubiprostone is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction [see warnings and precautions (5.5)]. risk summary following oral administration, concentrations of lubiprostone in plasma are below the level of quantitation;

United States - English - NLM (National Library of Medicine)

par pharmaceutical inc. - lubiprostone (unii: 7662kg2r6k) (lubiprostone - unii:7662kg2r6k) - lubiprostone is indicated for the treatment of chronic idiopathic constipation (cic) in adults. lubiprostone is indicated for the treatment of opioid-induced constipation (oic) in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation. limitations of use: effectiveness of lubiprostone in the treatment of opioid-induced constipation in patients taking diphenylheptane opioids (e.g., methadone) has not been established. [see clinical studies (14.2)] lubiprostone is indicated for the treatment of irritable bowel syndrome with constipation (ibs-c) in women at least 18 years old. lubiprostone is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction [see warnings and precautions (5.5)] . risk summary following oral administration, concentrations of lubiprostone in plasma are below the level of quantitation; however, one of the metabolites, m3, h

United States - English - NLM (National Library of Medicine)

amneal pharmaceuticals llc - lubiprostone (unii: 7662kg2r6k) (lubiprostone - unii:7662kg2r6k) - lubiprostone capsules are indicated for the treatment of chronic idiopathic constipation (cic) in adults. lubiprostone capsules are indicated for the treatment of opioid-induced constipation (oic) in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation. limitations of use: effectiveness of lubiprostone capsules in the treatment of opioid-induced constipation in patients taking diphenylheptane opioids (e.g., methadone) has not been established [see clinical studies (14.2)] . lubiprostone capsules are indicated for the treatment of irritable bowel syndrome with constipation (ibs-c) in women at least 18 years old. lubiprostone is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction [see warnings and precautions (5.5)] .   risk summary following oral administration, concentrations of lubiprostone in plasma are below the level of quantitati

United States - English - NLM (National Library of Medicine)

quality care products, llc - lubiprostone (unii: 7662kg2r6k) (lubiprostone - unii:7662kg2r6k) - lubiprostone is indicated for the treatment of chronic idiopathic constipation (cic) in adults. lubiprostone is indicated for the treatment of opioid-induced constipation (oic) in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation. limitations of use: effectiveness of lubiprostone in the treatment of opioid-induced constipation in patients taking diphenylheptane opioids (e.g., methadone) has not been established. [see clinical studies (14.2)] lubiprostone is indicated for the treatment of irritable bowel syndrome with constipation (ibs-c) in women at least 18 years old. lubiprostone is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction [see warnings and precautions (5.5)] . risk summary following oral administration, concentrations of lubiprostone in plasma are below the level of quantitation; however, one of the metabolites, m3, h

United States - English - NLM (National Library of Medicine)

natco pharma usa llc - lubiprostone (unii: 7662kg2r6k) (lubiprostone - unii:7662kg2r6k) - lubiprostone is indicated for the treatment of chronic idiopathic constipation (cic) in adults. lubiprostone is indicated for the treatment of opioid-induced constipation (oic) in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation. limitations of use : effectiveness of lubiprostone in the treatment of opioid-induced constipation in patients taking diphenylheptane opioids (e.g., methadone) has not been established. [see clinical studies (14.2)] lubiprostone is indicated for the treatment of irritable bowel syndrome with constipation (ibs-c) in women at least 18 years old. lubiprostone is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction [see warnings and precautions (5.5)]. risk summary following oral administration, concentrations of lubiprostone in plasma are below the level of quantitation; however, one of the metaboli

United States - English - NLM (National Library of Medicine)

par pharmaceutical, inc. - lubiprostone (unii: 7662kg2r6k) (lubiprostone - unii:7662kg2r6k) - lubiprostone capsules is indicated for the treatment of chronic idiopathic constipation (cic) in adults. lubiprostone capsules is indicated for the treatment of opioid-induced constipation (oic) in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation. limitations of use: effectiveness of lubiprostone capsules in the treatment of opioid-induced constipation in patients taking diphenylheptane opioids (e.g., methadone) has not been established. [see clinical studies (14.2)] lubiprostone capsules is indicated for the treatment of irritable bowel syndrome with constipation (ibs-c) in women at least 18 years old. lubiprostone capsules is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction [see warnings and precautions (5.5)] . risk summary following oral administration, concentrations of lubiprostone in plasma are below the level of quantit

United States - English - NLM (National Library of Medicine)

dr. reddy's laboratories inc. - lubiprostone (unii: 7662kg2r6k) (lubiprostone - unii:7662kg2r6k) - lubiprostone is indicated for the treatment of chronic idiopathic constipation (cic) in adults. lubiprostone is indicated for the treatment of opioid-induced constipation (oic) in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation. limitations of use: effectiveness of lubiprostone in the treatment of opioid-induced constipation in patients taking diphenylheptane opioids (e.g., methadone) has not been established. [see clinical studies (14.2)] lubiprostone is indicated for the treatment of irritable bowel syndrome with constipation (ibs-c) in women at least 18 years old. lubiprostone is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction [see warnings and precautions (5.5)] . risk summary following oral administration, concentrations of lubiprostone in plasma are below the level of quantitation; however, one of the metabolites, m3, h

United States - English - NLM (National Library of Medicine)

sun pharmaceutical industries, inc. - lubiprostone (unii: 7662kg2r6k) (lubiprostone - unii:7662kg2r6k) - lubiprostone is indicated for the treatment of chronic idiopathic constipation (cic) in adults. lubiprostone is indicated for the treatment of opioid-induced constipation (oic) in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation. limitations of use: effectiveness of lubiprostone in the treatment of opioid-induced constipation in patients taking diphenylheptane opioids (e.g., methadone) has not been established. [see clinical studies (14.2)] lubiprostone is indicated for the treatment of irritable bowel syndrome with constipation (ibs-c) in women at least 18 years old. lubiprostone is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction [see warnings and precautions (5.5)] . risk summary following oral administration, concentrations of lubiprostone in plasma are below the level of quantitation; however, one of the

United States - English - NLM (National Library of Medicine)

avkare - lubiprostone (unii: 7662kg2r6k) (lubiprostone - unii:7662kg2r6k) - lubiprostone capsules are indicated for the treatment of chronic idiopathic constipation (cic) in adults. lubiprostone capsules are indicated for the treatment of opioid-induced constipation (oic) in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation. limitations of use: effectiveness of lubiprostone capsules in the treatment of opioid-induced constipation in patients taking diphenylheptane opioids (e.g., methadone) has not been established [see clinical studies (14.2)] . lubiprostone capsules are indicated for the treatment of irritable bowel syndrome with constipation (ibs-c) in women at least 18 years old. lubiprostone is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction  [see warnings and precautions (5.5)] .   risk summary following oral

United States - English - NLM (National Library of Medicine)

golden state medical supply, inc. - lubiprostone (unii: 7662kg2r6k) (lubiprostone - unii:7662kg2r6k) - lubiprostone is indicated for the treatment of chronic idiopathic constipation (cic) in adults. lubiprostone is indicated for the treatment of opioid-induced constipation (oic) in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation. limitations of use: effectiveness of lubiprostone in the treatment of opioid-induced constipation in patients taking diphenylheptane opioids (e.g., methadone) has not been established. [see clinical studies (14.2)] lubiprostone is indicated for the treatment of irritable bowel syndrome with constipation (ibs-c) in women at least 18 years old. lubiprostone is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction [see warnings and precautions (5.5)] . risk summary following oral administration, concentrations of l